Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:aclidinium_bromide
gptkb:formoterol_fumarate |
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
R03AL05
|
| gptkbp:contraindication |
hypersensitivity to components
|
| gptkbp:form |
inhalation powder
|
| https://www.w3.org/2000/01/rdf-schema#label |
Duaklir Pressair
|
| gptkbp:indication |
maintenance treatment of COPD
|
| gptkbp:marketingAuthorizationHolder |
gptkb:AstraZeneca
|
| gptkbp:mechanismOfAction |
long-acting beta2-adrenergic agonist
long-acting muscarinic antagonist |
| gptkbp:notRecommendedFor |
asthma
|
| gptkbp:platform |
gptkb:Pressair_inhaler
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
inhalation
|
| gptkbp:sideEffect |
diarrhea
headache hypertension cough nasopharyngitis |
| gptkbp:usedFor |
chronic obstructive pulmonary disease
|
| gptkbp:bfsParent |
gptkb:AstraZeneca_US
|
| gptkbp:bfsLayer |
6
|